Having taken personal charge of leading its Taiwanese affiliate, Alvogen head Robert Wessman is looking to make Lotus Pharmaceuticals a global player in cancer therapies.
Robert Wessman will personally oversee the transformation of Alvogen’s majority-owned Taiwanese operation, Lotus Pharmaceuticals, into “a global leader in the field of oncology”. Wessman has become Lotus’ chairman, succeeding Andrew Lin, who had led the publicly-listed company since 2016, and will remain a board director.
“We are now entering the second phase in the development of Lotus,” commented Wessman, whose role as Alvogen’s chairman and...
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Steffen Wagner has taken over as Stada’s head of Germany, adding to his existing responsibilities in Europe, after Eelco Ockers stepped down from the role. Ockers’ departure comes as German generics giant Stada restructures its business to bring its branded and consumer health interests into closer alignment as part of a more streamlined model.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
